Hims & Hers Health, Inc. (HIMS) gains on deep earnings analysis
Hims & Hers Health, Inc. (HIMS) gained despite an EPS miss, as revenue beat estimates and growth momentum stayed intact. This deep-dive examines the mixed print, profitability pressure, Wegovy demand, analyst sentiment, and whether the stock’s gains are supported by fundamentals.
Hims & Hers Health (HIMS) reported mixed earnings, topping revenue estimates at $0.75 billion but missing EPS at -$0.10. The stock rose 0.57% to $31.77 as investors focused on rapid growth in weight loss and specialty care, though profitability remains the key risk. The quarter reinforces HIMS as a high-growth platform, but the earnings miss keeps the path to durable profits under scrutiny.
Hims & Hers Health, Inc. (HIMS) Gains After Mixed Earnings
Hims & Hers Health, Inc. (HIMS) delivered a mixed earnings print: revenue reached $0.75B against a $0.70B estimate, while EPS came in at -$0.1 versus -$0.04979 expected. Shares posted gains of 0.57% to $31.77 at the latest regular-session close, but the earnings miss keeps profitability in the foreground. Growth is doing the heavy lifting while earnings remain the loose bolt.
Key Takeaways
beat the revenue estimate with $0.75B, but missed the EPS estimate with a loss of -$0.1.
Revenue rose from $0.61B in the prior reported quarter to $0.75B, while net loss stayed at -$0.09B.
Weight loss showed strong operating momentum, with more than 125,000 Wegovy shipments fulfilled within six weeks of platform access.
CEO Andrew Dudum highlighted U.S. specialty care, global expansion, proactive care, and technology investments as the pillars of the long-term strategy.
The analyst consensus remains Hold, with 7 Buy ratings and 13 Hold ratings. No Sell ratings appear in the supplied consensus.
Analyst sentiment remains split. BofA cited softer oral Wegovy retention and a difficult second-half EBITDA ramp, while its recent price targets ranged from $29 to $37.
The central HIMS earnings result is simple. Revenue reached $0.75B, above the $0.70B estimate. EPS missed at -$0.1, compared with the expected -$0.04979.
The revenue figure also marked a sharp step up from the prior reported quarter's $0.61B. Recent quarterly revenue figures were $0.62B for the quarter ended Dec. 31, $0.60B for the quarter ended Sept. 30, and $0.54B for the quarter ended June 30, 2025. The sequence gives Hims & Hers Health a clear growth profile, even as earnings remain volatile.
Profitability tells a less comfortable story. Net loss totaled -$0.09B in the quarter ended June 30, matching the -$0.09B loss in the quarter ended March 31. The company reported net income of $0.02B in both the December and September quarters, followed by $0.04B in the June 2025 quarter.
EPS history adds useful perspective. HIMS reported EPS of -$0.4 on May 11, $0.07 on Feb. 23, $0.06 on Nov. 3, and $0.17 on Aug. 4, 2025. The latest -$0.1 result improved from the May loss, but it still fell below the current estimate and remains weaker than the positive results reported in the second half of 2025.
That combination matters for the stock. A revenue beat can support the growth narrative, but a profit miss limits the market's ability to reward growth at any price. HIMS is valued as a fast-expanding consumer health platform, so investors need the income statement to catch up with the customer and product story.
The strongest operating detail came from weight loss. Dudum said the company fulfilled more than 125,000 shipments for Novo Nordisk's Wegovy products within six weeks of offering direct access. He also said adoption in weight loss was near record levels, including demand beyond the New Year's and Super Bowl campaigns.
HIMS also reported momentum in newer specialties. Dudum identified testosterone, menopause, and labs as areas gaining traction. He said the testosterone offering now serves tens of thousands of men, and 95% of Hims customers using that support saw higher testosterone levels within two months.
These figures reinforce a growth catalyst view of HIMS. The platform is adding treatment categories and using partnerships with Novo Nordisk and Eli Lilly to widen its product range. However, the -$0.1 EPS result shows that scale has not produced a stable profit engine in the latest quarter.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
At the latest regular-session close, HIMS traded at $31.77, up 0.57%. Trading volume reached 16,101,097 shares, below the average volume of 18,372,749 shares. The modest gains show that the revenue beat and strategic growth narrative continued to support the stock, despite the EPS miss.
The broader analyst picture remains cautious. Consensus stands at Hold, with 7 Buy ratings and 13 Hold ratings across the supplied analyst set. A separate analyst summary places the consensus price target at $27.71.
BofA's recent actions show how divided the debate has become. On July 9, BofA raised its price target to $37 from $36 while maintaining a Neutral rating. On Aug. 1, BofA cut its target to $29 from $32 and maintained an Underperform rating.
BofA analyst Allen Lutz focused on retention rather than headline shipments. The firm cited “emerging signs” that new oral Wegovy members could retain at softer rates than expected. That concern matters because a large shipment count does not automatically create durable recurring revenue.
“emerging signs” that retention of new oral Wegovy members could be softer than expected - Allen Lutz, BofA Securities
BofA also argued that the implied second-half EBITDA ramp would be difficult to achieve. That view clashes with Dudum's confident growth outlook and captures the core HIMS debate: the platform is expanding quickly, but the economics of that expansion remain under pressure.
The analyst record also includes a March 10 Citigroup upgrade from Sell to Neutral, with a $24 price target. MarketBeat's recent summary recorded 2 downgrades and 1 upgrade over the prior 90 days. Together, those actions point to active debate rather than a settled bullish or bearish consensus.
CEO Strategy: From Telehealth Brand to Global Health Platform
CEO Andrew Dudum used the HIMS earnings call to frame the company as more than a single-condition telehealth provider. He pointed to nearly 2.6 million customers, a planned Eucalyptus acquisition, new specialties, and deeper technology capabilities.
“2026 has proven to be a year of accelerating growth, which reinforces our confidence in our ambitious 2030 targets.” - Andrew Dudum, CEO, Earnings Call
Dudum's strategy rests on four connected ideas. First, the U.S. business can expand through specialties such as testosterone, menopause, and labs. Second, global scale can strengthen relationships with pharmaceutical, biotech, and diagnostic partners. Third, proactive care can deepen customer relationships. Fourth, data and artificial intelligence can improve the platform as customer interactions grow.
“We are creating an opportunity for longer-term relationships with our customers.” - Andrew Dudum, CEO, Earnings Call
The Eucalyptus acquisition adds another strategic layer. Dudum said the transaction is planned to close in the second half of 2026 and would extend Hims & Hers Health's consumer health presence across Australia, the U.K., Germany, Japan, and Canada.
The strategic case is compelling when measured by reach and product breadth. Yet the latest EPS miss gives analysts a reason to question how quickly those investments can translate into earnings. In plain English, the company is building a larger machine, while the market is asking when the machine will generate reliable cash profits.
HIMS delivered the kind of revenue growth that supports its long-term platform story, but the -$0.1 EPS result keeps valuation and profitability risks in focus. Weight loss shipments, new specialties, and global expansion strengthen the growth case, while BofA's retention concerns explain the Hold-heavy analyst view. For investors, the stock's next leg of gains requires the platform's expanding reach to produce more dependable earnings.
+Did Hims & Hers Health (HIMS) beat revenue in its latest earnings report?
Yes. Hims & Hers Health reported revenue of $0.75 billion versus the $0.70 billion estimate. Revenue also increased from $0.61 billion in the prior reported quarter.
+Why did HIMS stock rise after earnings even though EPS missed?
The market focused on the revenue beat and strong operating momentum, especially in weight loss and specialty care. Shares still closed up 0.57% at $31.77, but the EPS miss kept profitability concerns in view.
+What did Hims & Hers say about Wegovy demand?
CEO Andrew Dudum said Hims fulfilled more than 125,000 Wegovy shipments within six weeks of offering direct access. He also said weight-loss adoption was near record levels, including demand beyond the New Year's and Super Bowl campaigns.
+What is Wall Street's view on HIMS after the earnings report?
The supplied analyst consensus remains Hold, with 7 Buy ratings and 13 Hold ratings and no Sell ratings. BofA has pointed to softer oral Wegovy retention and a difficult second-half EBITDA ramp as key concerns.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on HIMS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
